Frontier Pharma: Chronic Obstructive Pulmonary Disease (COPD) - Identifying and Commercializing First-in-Class Innovation market growth market research report is the latest addition to RnRMarketResearch.com and its collection of therapeutics business intelligence reports aimed to help take better decisions. The COPD marketed products landscape consists of pharmacological therapies aimed at managing the symptoms associated with COPD, although none of the available therapies have been shown to modify long-term disease progression. The current COPD pipeline consists of 212 active products in development. Initial analysis revealed a small presence of first-in-class products, constituting 16.5% of the pipeline. In comparison to other indications, this is relatively low; however, there are some promising trends within COPD product development. The Preclinical Phase of development is the most active in terms of first-in-class products. This diminishes throughout clinical development, with only two such products being present in Phase III. However, if either of these products is approved, they would represent the first, first-in-class products to be approved for COPD since roflumilast, which was approved in 2011 by the FDA and in 2010 in the EU. Roflumilast was the first novel therapy for COPD in almost 20 years, which demonstrates the infrequency at which first-in-class products enter the COPD market. So to have two first-in-class products in Phase III and six in Phase II is a promising sign. Complete market report of “COPD Market ” addition with 03 market data tables and 41 figures, spread across 53 pages is http://www.rnrmarketresearch.com/frontier-pharma-chronic-obstructive-pulmonary-disease-copd-identifying-and-commercializing-first-in-class-innovation-market-report.html . Scope: • The COPD market has benefited from notable additions in recent years. • The pipeline contains a range of molecule types and molecular targets, including those that are well established in COPD and novel, first-in-class therapies. • First-in-class products differ substantially in their clinical potential, based on their alignment to disease causing pathways. • There have been 59 licensing deals and 41 co-development deals pertaining to COPD products since 2006. Request sample @ http://www.rnrmarketresearch.com/contacts/request-sample?rname=461571 . Reasons to buy: • Understand the current clinical and commercial landscape. It includes a comprehensive study of disease pathogenesis, diagnosis, prognosis and the treatment options available at each stage of diagnosis. • Visualize the composition of the COPD market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market. • Analyze the COPD pipeline and stratify by stage of development, molecule type and molecular target. There are promising signs in the pipeline that the industry is seeking novel approaches to treating COPD. • Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been reviewed in greater detail. • Identify commercial opportunities in the COPD deals landscape by analyzing trends in licensing and co-development deals and producing a curated list of COPD therapies that are not yet involved in deals and may be potential investment opportunities.